With the reality of Brexit already impacting the UK’s clinical trials environment, Zamas Lam (QPS; DE, USA) discusses the effect this will have on bioanalytical research, and suggests 10 questions to ask when relocating UK-based preclinical and bioanalysis research projects.
Find out what Naidong Weng (Janssen Research and Development) has to say about the future of bioanalytical outsourcing, in this expert interview.
Find out what Marco Michi (Aptuit) has to say about the future of bioanalytical outsourcing, in this expert interview.
Find out what Kevin Vernarec (QPS) thinks about how outsourcing might change in the future in this expert interview.
Find out what Song Li (Frontage) has to say about the future of bioanalytical outsourcing, in this video interview.
In part 1 of this 3-part panel discussion filmed in Barcelona our panel of experts discuss the issue of outsourcing and what priorities need considering when making a purchasing decision.
In the final part of this 3-part panel discussion, our experts talk through the recent changes in the type of molecules and technologies the field are working with and what new technologies need to emerge to overcome current problems.
In our interview Chad talks about his career highlights, advice that he would share with his younger self about patience, and how his bioanalytical hero has helped in pushing him towards his goals.
Afshin Safavi, shares his perspective on the past, present and future of bioanalytical outsourcing (BioAgilytx)
Afshin Safavi, Founder and Global Chief Scientific Officer at BioAgilytix (NC, USA) shares his perspective on the past, present and future of bioanalytical outsourcing.
Business of bionanalysis: The impact of mergers, acquisitions, and organic growth on bioanalytical sciences
In this final video the Business of bioanalysis panelists discuss the impact of mergers, acquisitions, and organic growth on bioanalytical sciences. The scientific community in which we work goes beyond affiliation, movement of bioanalytical scientists and talent between CRO, pharmaceutical and instrument vendors. The business is robust, while management of corporate culture is critical.